News and Announcements

Syncona NAV rises as Beacon breakthrough boosts valuation

By Benjamin Chiou

Date: Thursday 12 Nov 2026

(Sharecast News) - Life sciences investor Syncona reported a 3% increase in net asset value per share in the first half, driven by positive clinical trial results from portfolio company Beacon Therapeutics, as it reiterated plans to return at least £250m to shareholders.
Net asset value per share rose to 175.7p...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page